Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
2011

Effects of aleglitazar on blood sugar and fat levels in monkeys

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): Barbara C Hansen, Xenia Tigno, Agnes Bénardeau, Markus Meyer, Elena Sebokova, Jacques Mizrahi

Primary Institution: University of South Florida

Hypothesis

Does aleglitazar improve glycemic and lipid parameters in a primate model of metabolic syndrome?

Conclusion

Aleglitazar has beneficial effects on both lipid and glucose parameters and may help reduce cardiovascular risk factors in patients with type 2 diabetes.

Supporting Evidence

  • Aleglitazar reduced triglyceride levels by an average of 89%.
  • It increased HDL cholesterol levels by 125%.
  • Aleglitazar improved insulin sensitivity by 60%.
  • Mean body weight decreased by 5.9% with aleglitazar treatment.

Takeaway

Aleglitazar is a medicine that helps lower bad fats and blood sugar levels in monkeys, which might help people with diabetes.

Methodology

The study involved a 135-day efficacy assessment in six rhesus monkeys, measuring blood parameters before, during, and after treatment with aleglitazar.

Limitations

The study was conducted on monkeys, and the results may not directly translate to humans.

Participant Demographics

Six adult male rhesus monkeys with metabolic syndrome.

Statistical Information

P-Value

P = 0.0035

Digital Object Identifier (DOI)

10.1186/1475-2840-10-7

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication